- Home
- FLY vs RYTM Comparison
FLY vs RYTM Comparison
Compare FLY & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLY | RYTM |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.4B |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FLY | RYTM |
|---|---|---|
| Price | $29.83 | $112.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $40.38 | ★ $128.54 |
| AVG Volume (30 Days) | ★ 3.7M | 751.8K |
| Earning Date | 11-12-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $111,216,000.00 | ★ $174,334,000.00 |
| Revenue This Year | $156.28 | $47.34 |
| Revenue Next Year | $189.66 | $55.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 101.35 | 54.92 |
| 52 Week Low | $16.00 | $45.91 |
| 52 Week High | $73.80 | $122.20 |
Technical Indicators
Market Signals| Indicator | FLY | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 59.06 |
| Support Level | N/A | $96.20 |
| Resistance Level | N/A | $103.20 |
| Average True Range (ATR) | 0.00 | 4.79 |
| MACD | 0.00 | 0.20 |
| Stochastic Oscillator | 0.00 | 93.19 |
Price Performance
Historical ComparisonAbout FLY Firefly Aerospace Inc.
Firefly Aerospace Inc is a space and defense technology company with an established track record of success providing comprehensive mission solutions to national security, government, and commercial customers. The company enables government and commercial customers to launch, land and operate in space - Anywhere, Anytime.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.